Summary statistics - qualitative results

EQA round: AIH2/26 - Autoimmune Liver Diseases

Deadline: 16.10.2026

Setup: groups - M (measurement principle)

AV = assigned value
CVP = consensus of all participants
>>> ... expected result
> ... acceptable result
± ... result not assessed

N_{tot} = total number of the results
N_{rel} = relative number of the results

N_{eva} = number of the results assessed
N_{suc} = number of successful results
S_{rel} = relative success

Test / Sample / Group	AV	N_{tot}	N_{rel} [%]	Result	Success N_{eva}	N_{suc}	S_{rel} [%]
(451) **AMA**		53			53	49	92
Sample A		53			53	53	100
(0) Not specified	CVP >>>	53	100	Negative			
Sample B		53			53	49	92
(0) Not specified		4	7,5	Inconclusive result (borderline)			
	CVP >>>	49	92	Positive			
(456) **AMA-M2**		66			66	66	100
Sample A		66			66	66	100
(1) Fluorescent methods	CVP >>>	1	1,5	Negative			
(2) EIA methods	CVP >>>	13	20	Negative			
(5) Immunoblotting	CVP >>>	51	77	Negative			
(99) Another measurement principle	CVP >>>	1	1,5	Negative			
Sample B		66			66	66	100
(1) Fluorescent methods	CVP >>>	1	1,5	Positive			
(2) EIA methods	CVP >>>	13	20	Positive			
(5) Immunoblotting	CVP >>>	51	77	Positive			
(99) Another measurement principle	CVP >>>	1	1,5	Positive			
(454) **anti-gp210**		60			60	59	98
Sample A		60			60	60	100
(2) EIA methods	CVP >>>	4	6,7	Negative			
(5) Immunoblotting	CVP >>>	55	92	Negative			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			
Sample B		60			60	59	98
(2) EIA methods	CVP >>>	4	6,7	Negative			
(5) Immunoblotting	CVP >>>	54	90	Negative			
		1	1,7	Inconclusive result (borderline)			
(99) Another measurement principle	CVP >>>	1	1,7	Negative			
(457) **anti-LC-1**		63			63	63	100
Sample A		63			63	63	100
(2) EIA methods	CVP >>>	7	11	Negative			
(5) Immunoblotting	CVP >>>	55	87	Negative			
(99) Another measurement principle	CVP >>>	1	1,6	Negative			
Sample B		63			63	63	100
(2) EIA methods	CVP >>>	7	11	Negative			
(5) Immunoblotting	CVP >>>	55	87	Negative			
(99) Another measurement principle	CVP >>>	1	1,6	Negative			
(452) **anti-LKM**		46			46	46	100
Sample A		46			46	46	100
(0) Not specified	CVP >>>	46	100	Negative			
Sample B		46			46	46	100
(0) Not specified	CVP >>>	46	100	Negative			
(455) **anti-LKM1**		66			66	66	100
Sample A		66			66	66	100
(1) Fluorescent methods	CVP >>>	1	1,5	Negative			
(2) EIA methods	CVP >>>	12	18	Negative			
(5) Immunoblotting	CVP >>>	51	77	Negative			
(99) Another measurement principle	CVP >>>	2	3	Negative			
Sample B		66			66	66	100
(1) Fluorescent methods	CVP >>>	1	1,5	Negative			
(2) EIA methods	CVP >>>	12	18	Negative			
(5) Immunoblotting	CVP >>>	51	77	Negative			
(99) Another measurement principle	CVP >>>	2	3	Negative			
(458) **anti-SLA**		65			65	65	100
Sample A		65			65	65	100
(2) EIA methods	CVP >>>	11	17	Negative			
(5) Immunoblotting	CVP >>>	53	82	Negative			
(99) Another measurement principle	CVP >>>	1	1,5	Negative			
Sample B		65			65	65	100
(2) EIA methods	CVP >>>	11	17	Negative			
(5) Immunoblotting	CVP >>>	53	82	Negative			
(99) Another measurement principle	CVP >>>	1	1,5	Negative			
(459) **anti-sp100**		60			60	59	98
Sample A		60			60	59	98
(2) EIA methods	CVP >>>	4	6,7	Negative			

Summary statistics - qualitative results

EQA round: AIH2/26 - Autoimmune Liver Diseases

Deadline: 16.10.2026

Setup: groups - M (measurement principle)

Test / Sample / Group		AV	N_{tot}	N_{rel} [%]	Result	Success N_{eva}	Success N_{suc}	Success S_{rel} [%]
(5) Immunoblotting	CVP	>>>	54	90	Negative			
			1	1,7	Positive			
(99) Another measurement principle	CVP	>>>	1	1,7	Negative			
Sample B			60			60	60	100
(2) EIA methods	CVP	>>>	4	6,7	Negative			
(5) Immunoblotting	CVP	>>>	55	92	Negative			
(99) Another measurement principle	CVP	>>>	1	1,7	Negative			
(453) **SMA**			56			56	56	100
Sample A			56			56	56	100
(0) Not specified	CVP	>>>	56	100	Negative			
Sample B			56			56	56	100
(0) Not specified	CVP	>>>	56	100	Negative			